Financial reports
10-K
2023 FY
Annual report
18 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
ARS
2022 FY
Annual report to shareholders
24 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
Current reports
8-K
Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update
18 Mar 24
8-K/A
Submission of Matters to a Vote of Security Holders
16 Feb 24
8-K
Changes in Registrant's Certifying Accountant
8 Dec 23
8-K/A
Submission of Matters to a Vote of Security Holders
26 Sep 23
8-K
Departure of Directors or Certain Officers
20 Sep 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
20 Sep 23
8-K
Changes in Registrant's Certifying Accountant
4 Aug 23
8-K
Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102
1 Aug 23
8-K
Entry into a Material Definitive Agreement
26 Jun 23
8-K
Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides
31 Mar 23
Registration and prospectus
S-8
Registration of securities for employees
12 Apr 24
424B3
Prospectus supplement
8 Sep 23
S-3
Shelf registration
29 Aug 23
D
$25.01 mm in equity / options, sold $25.01 mm, 27 investors
9 Aug 23
8-A12B/A
Registration of securities on exchange (amended)
26 Jun 23
S-8
Registration of securities for employees
31 Mar 23
424B5
Prospectus supplement for primary offering
12 Aug 22
8-A12B
Registration of securities on exchange
12 Jul 22
S-8
Registration of securities for employees
24 Jun 22
424B5
Prospectus supplement for primary offering
31 Mar 22
Proxies
DFAN14A
Additional proxy materials by non-management
14 Sep 23
DFAN14A
Additional proxy materials by non-management
6 Sep 23
DEFA14A
Additional proxy soliciting materials
1 Sep 23
DFAN14A
Additional proxy materials by non-management
31 Aug 23
DEFA14A
Additional proxy soliciting materials
31 Aug 23
DFAN14A
Additional proxy materials by non-management
25 Aug 23
DEFC14A
Proxy in contested solicitation
25 Aug 23
DEFC14A
Proxy in contested solicitation
24 Aug 23
PRRN14A
Revised preliminary proxy statement filed by non-management
17 Aug 23
PREC14A
Preliminary proxy with contested solicitation
2 Aug 23
Other
EFFECT
Notice of effectiveness
11 Sep 23
CORRESP
Correspondence with SEC
6 Sep 23
UPLOAD
Letter from SEC
5 Sep 23
EFFECT
Notice of effectiveness
8 Jun 21
UPLOAD
Letter from SEC
3 Jun 21
CORRESP
Correspondence with SEC
3 Jun 21
EFFECT
Notice of effectiveness
14 May 20
CORRESP
Correspondence with SEC
13 May 20
CORRESP
Correspondence with SEC
12 May 20
CORRESP
Correspondence with SEC
12 May 20
Ownership
4
Antony A Riley
2 Apr 24
4
Paul A. Wagner
2 Apr 24
4
BARBARA K FINCK
25 Mar 24
4
Antony A Riley
25 Mar 24
4
Paul A. Wagner
25 Mar 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G
TYBOURNE CAPITAL MANAGEMENT (HK) LTD
14 Feb 24
SC 13G/A
ALGER ASSOCIATES INC
14 Feb 24
SC 13G/A
Farallon Capital Partners, L.P.
14 Feb 24
SC 13D/A
BML Investment Partners, L.P.
11 Jan 24